RTP Mobile Logo

Monday, April 1, 2019, Atlanta, Georgia, 7:00 PM – 9:00 PM

Exploring the Biology and Current Research Database Supporting the Use of PARP Inhibition as a Therapeutic Strategy for Patients with Inherited and Sporadic Cancers

Event Details

Location:
Hyatt Regency Atlanta
265 Peachtree St NE
Atlanta, GA 30303
Hotel Phone: (404) 577-1234

Time:
6:30 PM – 7:00 PM — Registration and Buffet Dinner
7:00 PM – 9:00 PM — Educational Meeting

Meeting Room:
Centennial I-II (Ballroom Level)

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Faculty:
Emmanuel S Antonarakis, MD
Associate Professor of Oncology and Urology
Johns Hopkins University
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Kathleen Moore, MD
Jim and Christy Everest Endowed Chair in
Cancer Research
Associate Director, Clinical Research
Director, Oklahoma TSET Phase I Program
Stephenson Cancer Center
Associate Professor, Section of
Gynecologic Oncology
Director, Gynecologic Oncology Fellowship
Department of Obstetrics and Gynecology
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma


Michael J Pishvaian, MD, PhD
Phase I Program Director
Medical Director of the CRMO
Associate Professor
Lombardi Comprehensive Cancer Center
Washington, DC

Melinda Telli, MD
Associate Professor of Medicine
Stanford University School of Medicine
Leader, Breast Oncology Clinical Research Group
Stanford Cancer Institute
Stanford, California


Moderator:
Neil Love, MD
Research To Practice
Miami, Florida

This symposium is accredited by Research To Practice and supported by a grant from AstraZeneca Pharmaceuticals LP. This is not an official program of the American Association for Cancer Research Annual Meeting.

Agenda

Meeting Agenda and Format

This unique activity will be divided into 4 modules, each focused on a single therapeutic area. Each module will feature a discussion of audience polling results and a faculty presentation reviewing emerging research. At numerous points, Dr Love will interject questions and comments, including those obtained from meeting attendees using an “oncology chat room” on the iPads provided. The faculty members not presenting at that time will also be brought into these discussions to ensure that a variety of perspectives emerge.

MODULE 1: PARP Inhibition as a Therapeutic Strategy — Ovarian Cancer (OC) at the Vanguard — Dr Moore

  • Preclinical and clinical data informing current understanding of mechanisms of PARP inhibition (eg, base excision repair blockade, PARP trapping)
  • Frequency and significance of germline and somatic BRCA mutations and other genomic signatures that may predict benefit from PARP inhibition; biologic basis for response to PARP inhibitors in patients with wild-type OC
  • Design of, entry criteria for and efficacy and safety results from the Phase III SOLO-1 trial evaluating maintenance olaparib after first-line platinum-based chemotherapy for patients with advanced OC and a BRCA mutation
  • Differences in metabolism and drug-drug interactions among the FDA-approved PARP inhibitors; impact on the emergence of select agent-specific toxicities
  • Other ongoing Phase III clinical trials evaluating PARP inhibition alone or in combination with other systemic approaches in the first-line setting (eg, PRIMA, PAOLA-1, ATHENA)
  • Proposed mechanisms of PARP inhibitor resistance; implications for investigational combination approaches and future research efforts

MODULE 2: Current and Emerging Role of PARP Inhibitors in Metastatic Breast Cancer (mBC) — Dr Telli

  • Prevalence and prognostic impact of BRCA germline mutations among patients with mBC
  • Differences in relative PARP trapping potency, metabolism and drug-drug interactions among FDA-endorsed and investigational PARP inhibitors; effect on activity, toxicity and practical use
  • Phase III data sets supporting the FDA approvals for olaparib (OlympiAD) and talazoparib (EMBRACA) for patients with mBC and a BRCA germline mutation
  • Effect of hormone receptor status, prior platinum exposure and number of lines of prior chemotherapy on the activity of PARP inhibitors
  • Mechanistic basis for potential synergy between PARP inhibitors and immune checkpoint inhibition; published research data and ongoing studies combining these agents
  • Biologic rationale for the investigation of PARP inhibitors in combination with other therapeutic modalities (chemotherapy, anti-angiogenic agents, endocrine therapy, et cetera)

MODULE 3: Pancreatic Cancer and PARP Inhibition — What We Know and What We Don’t — Dr Pishvaian

  • Early clinical experience with the use of PARP inhibitors (eg, olaparib, rucaparib, veliparib) in patients with pancreatic adenocarcinoma (PAD) and a documented BRCA mutation
  • Design of, eligibility criteria for and progression-free survival advantage observed in the Phase III POLO trial evaluating olaparib as maintenance therapy for patients with metastatic PAD and a germline BRCA mutation whose disease has not progressed on first-line platinum-based chemotherapy
  • Other ongoing clinical trials of PARP inhibition in patients with PAD and a documented germline or somatic BRCA mutation
  • Biologic similarities and differences between BRCA-mutated cancers and those exhibiting BRCAness
  • Frequency of alternative DNA damage-repair abnormalities (eg, ATM, PALB2, FANCB) in pancreatic cancer; rationale for and potential benefit of PARP inhibition

MODULE 4: DNA Repair Deficiency in Advanced Prostate Cancer and the Potential Role of PARP Inhibition — Dr Antonarakis

  • Prevalence of DNA repair defects in prostate cancer; frequency in localized versus metastatic disease
  • Spectrum of inherited germline DNA repair mutations in metastatic prostate cancer; incidence of BRCA1/2 mutations
  • Available clinical trial data supporting FDA breakthrough therapy designations for olaparib (TOPARP-A) and rucaparib (TRITON2) for patients with progressive metastatic castration-resistant prostate cancer (mCRPC)
  • Ongoing Phase III trials (eg, PROfound, TRITON3) evaluating PARP inhibitors in men with progressive mCRPC
  • Biologic rationale for and ongoing evaluation of PARP inhibitors in combination with other anticancer therapies (eg, secondary hormonal agents, immune checkpoint inhibitors)

CE Information

Target Audience:
This activity is intended for medical oncologists, hematologists, surgeons, radiation oncologists and other healthcare professionals involved in basic, translational and clinical cancer research or treatment.

Learning Objectives:
At the conclusion of this activity, participants should be able to:

  • Comprehend how DNA damage-repair pathway abnormalities can be exploited via PARP inhibition to elicit therapeutic benefit.
  • Consider the correlation between BRCA1/2 mutations and the development of hereditary cancers, and counsel patients with these genetic abnormalities regarding their long-term outlook and therapeutic options.
  • Appraise available guideline recommendations and consensus statements on the indications and evidence-based modalities for genetic testing in ovarian and breast cancer, and use the results of these assessments to guide long-term treatment planning, including clinical trial accrual.
  • Appreciate available clinical trial data with FDA-approved PARP inhibitors for patients with ovarian cancer to safely integrate these agents into routine clinical care.
  • Evaluate the recent FDA approvals of olaparib and talazoparib for patients with HER2-negative metastatic breast cancer harboring a germline BRCA mutation, and discern how these agents can be appropriately and safely integrated into routine clinical practice.
  • Assess the pharmacologic, pharmacodynamic and pharmacokinetic similarities and differences among the commercially available and investigational PARP inhibitors to better understand the activity and toxicities associated with these agents.
  • Describe the rationale for testing patients with metastatic prostate cancer or pancreatic adenocarcinoma for mutations in homology-directed DNA repair predisposition genes, and advise individuals found to harbor these genetic abnormalities about participation in clinical trials evaluating PARP inhibition.
  • Describe mechanisms of acquired tumor resistance to PARP inhibitors, and identify investigational therapeutic opportunities to circumvent this process.
  • Understand the biologic rationale for the design of ongoing clinical trials evaluating novel therapeutic approaches with PARP inhibitors for patients with DNA damage-repair deficiencies.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporters:
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

Location

Hyatt Regency Atlanta
265 Peachtree St NE
Atlanta, GA 30303
Hotel Phone: (404) 577-1234

Meeting Room:
Centennial I-II (Ballroom Level)

 

Registration

This activity is intended for medical oncologists, hematologists, surgeons, radiation oncologists and other healthcare professionals involved in basic, translational and clinical cancer research or treatment.

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Registration for clinicians in practice

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
 
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least one half hour prior to the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.